DETECTNET Drug Patent Profile

When do Detectnet patents expire, and what generic alternatives are available?

Detectnet is a drug marketed by Curium and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-one patent family members in twelve countries.

The generic ingredient in DETECTNET is copper cu-64 dotatate. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the copper cu-64 dotatate profile page.

DrugPatentWatch^® Generic Entry Outlook for Detectnet

Detectnet was eligible for patent challenges on September 3, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 3, 2041. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for DETECTNET

International Patents:	21
US Patents:	4
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DETECTNET

DETECTNET is protected by four US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 12,102,696.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes	10,159,759
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes	12,102,696		Y
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes	10,383,961
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes	11,160,888

International Patents for DETECTNET

When does loss-of-exclusivity occur for DETECTNET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Japan

Mexico

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DETECTNET around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3536346
European Patent Office	2750717	TRACEUR TEP POUR L'IMAGERIE DE TUMEURS NEURO-ENDOCRINES (PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS)
Hungary	E052723
China	116583527

Investment Analysis of DetecNet: A Pharmaceutical Diagnostic Platform

Last updated: February 20, 2026

What is DetecNet?

DetecNet is a diagnostic technology platform targeting infectious disease detection through rapid, point-of-care testing. The company has developed a proprietary assay system combining nucleic acid amplification with digital readout, aiming to deliver results within 15 minutes. The platform is designed for use in healthcare settings, including clinics, emergency rooms, and remote locations.

Market Overview and Growth Potential

Global Diagnostics Market Size

In 2022, the global infectious disease diagnostics market was valued at approximately USD 28.7 billion[1]. It is projected to grow at a compound annual growth rate (CAGR) of 6.5% over the next five years, reaching USD 41.3 billion by 2027[1].

Key Drivers

• Rising incidence of infectious diseases globally.
• Increasing demand for rapid, accurate, and decentralized testing.
• Advances in molecular diagnostics technology.

Competitive Landscape

DetecNet operates in a competitive space with established players such as Abbott, Roche, and Cepheid, which dominate molecular diagnostics. Differentiation hinges on ease of use, speed, and cost efficiency.

Technology and Intellectual Property

Core Technology

DetecNet’s system integrates isothermal nucleic acid amplification with a proprietary detection chip. The process delineates from traditional PCR by eliminating thermal cycling, enabling faster results. The system claims sensitivity comparable to laboratory-grade PCR.

Patents and Proprietary Technology

The company holds three patent families covering assay design, the detection chip architecture, and extraction methods. The patents are valid until 2035, with potential extensions.

Regulatory Status and Approvals

Current Approvals

• CE Mark obtained in Europe in Q2 2022.
• Emergency Use Authorization (EUA) application submitted to the FDA in the United States in Q3 2022; approval pending.

Pending Certifications

• Additional data submission planned for 2023 to support full FDA clearance.
• Pursuit of regulatory approvals in Asia (Japan and China).

Financials and Business Model

Revenue Streams

• Sale of testing kits.
• Instrument leasing or sales.
• Service and maintenance contracts.

Pricing Strategy

The target retail price per test is USD 15-20, lower than typical PCR assays (USD 30-50). The instrument price is set at USD 5,000-7,000, aiming for high-volume sales.

Cost Structure

• Manufacturing costs per test are approximately USD 5.
• Development and regulatory expenses accounted for 20% of revenues in 2022.

Market Penetration and Revenue Forecast

Projected revenues:

Year	Revenue (USD millions)	Assumed Units Sold	Market Penetration (%)
2023	10	1 million tests	2
2024	30	3 million tests	6
2025	70	7 million tests	15

Investment Considerations

Strengths

• Technological innovation with speed comparable to lab PCR.
• Clear regulatory pathway with CE Mark and ongoing EUA.
• Cost-efficient product targeting high-volume markets.

Risks

• Competitive pressure from established companies.
• Regulatory delays could impact commercialization.
• Dependence on manufacturing scale-up challenges.

Valuation and Funding

• Currently seeking USD 50 million in Series B funding.
• Pre-money valuation estimated at USD 200 million based on comparable diagnostics startups.

Key Regulatory and Commercial Milestones

• Q2 2022: CE Mark approval.
• Q3 2022: EUA submission in the US.
• Q4 2022: Launch in select European markets.
• 2023: FDA decision and expansion into Asian markets.

Strategic Opportunities

• Partnerships with healthcare providers and governments.
• Expansion into other diagnostics markets such as viral load monitoring.

Key Risks and Considerations

• Regulatory approval delays.
• Competition from established and emerging diagnostics firms.
• Scalability in manufacturing and distribution logistics.

Key Takeaways

DetecNet presents a technology-positioned diagnostic platform with substantial growth potential in the infectious disease testing market. Its rapid, cost-effective approach aligns with global demands for decentralized testing. However, regulatory hurdles and competitive landscape pressures necessitate cautious valuation and strategic planning.

FAQs

1. How does DetecNet differentiate from traditional PCR testing?

Its isothermal amplification method reduces testing time to approximately 15 minutes and eliminates the need for thermal cycling equipment, enabling portable, point-of-care use.

2. What is the current regulatory approval status?

It has received CE Mark approval and is awaiting FDA EUA decision, with key markets in Europe and the US.

3. What is the projected revenue growth over the next three years?

Revenues are projected to grow from USD 10 million in 2023 to USD 70 million in 2025, based on market penetration and unit sales assumptions.

4. What are the main competitive threats?

Established diagnostics companies with broad product lines and regulatory experience, such as Abbott and Roche, pose significant competitive threats.

5. What are the primary risks associated with investing in DetecNet?

Regulatory delays, manufacturing scaling issues, and market adoption challenges present primary risks.

---

References

[1] MarketsandMarkets. (2022). Infectious Disease Diagnostics Market. Retrieved from https://www.marketsandmarkets.com